Trial Profile
Targeted Therapy With BRAF And MEK Inhibition For Neurological Benefit In Patients With Brain Metastases From BRAF-Mutated Melanoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2019
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary) ; Vemurafenib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- 06 Dec 2016 New trial record
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.